Key Points
- Whitehawk CEO David James Lennon sold 5,100 shares on March 2 at an average price of $3.31 for $16,881, reducing his stake by 10.27% to 44,579 shares (≈$147,556), according to an SEC filing.
- WHWK shares opened at $4.03 (52‑week range $1.39–$4.48) with a market cap of $189.9M and a P/E of 28.79; analysts are mixed (two Buys, one Hold, one Sell) with a consensus rating of "Hold" and a consensus target of $6.50.
- Institutions own 52.08% of the company, and several funds recently initiated or increased positions (notably Jane Street, which raised its stake by 177.3% to 69,931 shares).
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00. Following the sale, the chief executive officer owned 44,579 shares in the company, valued at $147,556.49. The trade was a 10.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Whitehawk Therapeutics Stock Down 1.2%
Shares of WHWK opened at $4.03 on Wednesday. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48. The company has a 50-day simple moving average of $2.93 and a 200-day simple moving average of $2.44. The company has a market capitalization of $189.93 million, a PE ratio of 28.79 and a beta of 0.51.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a "buy" rating and a $7.00 price target for the company. Oppenheimer began coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $6.50.
View Our Latest Analysis on Whitehawk Therapeutics
Institutional Trading of Whitehawk Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of WHWK. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth about $51,000. Dimensional Fund Advisors LP purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $84,000. Marshall Wace LLP acquired a new position in Whitehawk Therapeutics during the fourth quarter worth approximately $164,000. Finally, Jane Street Group LLC raised its holdings in shares of Whitehawk Therapeutics by 177.3% in the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company's stock worth $169,000 after purchasing an additional 44,716 shares during the period. Hedge funds and other institutional investors own 52.08% of the company's stock.
About Whitehawk Therapeutics
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
